Date: Jan 06, 2016 Source: PR Newswire (
click here to go to the source)
BIRMINGHAM, Ala., Jan. 6, 2016 /PRNewswire/ -- Gem Pharmaceuticals announced today that the U.S. Food and Drug Administration has granted orphan drug designation to GPX-150, the Company's lead product candidate that is currently undergoing a Phase 2 clinical trial in patients suffering from soft tissue sarcoma. This study is fully enrolled, with final safety and efficacy data expected to be available by Q-4 2016.
